Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Neoplasms 6Prostatic Neoplasms 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Locally Advanced Esophageal or GE Junction Cancer 1Hormone Refractory Prostate Cancer 1Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 82venetoclax 56ibrutinib 46obinutuzumab 43Bendamustine Hydrochloride 40idelalisib 30Cyclophosphamide 29acalabrutinib 28fludarabine 27Chlorambucil 27pirtobrutinib 18ublituximab 16ofatumumab 16zanubrutinib 14umbralisib 14Lenalidomide 11fludarabine phosphate 9Alemtuzumab 9navitoclax 7duvelisib 7Azacitidine 5lumiliximab 4aflibercept 4TRU 016 4Interleukin-2 4BI 836826 4ARQ531 4tafasitamab 3motexafin gadolinium 3dinaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Lymphocytic, Chronic, B-Cell × gossypol acetic acid × Clear all
NCT00275431 2011-06-29

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

Ascenta Therapeutics

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00286780 2010-08-13

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Ascenta Therapeutics

Phase 2 Completed
19 enrolled
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡